ZORYVE foam 0.3% — Topline data
Q4 2026
The Company expects to report results, as well as decisions on program advancement in these indications, in the fourth quarter of 2026 and first quarter of 2027, respectively.Source filing
ARQT biotech catalysts & pipeline
ARCUTIS BIOTHERAPEUTICS INC · Data as of 2026-09-08
Upcoming catalysts
ZORYVE foam 0.3% — Regulatory decision
Q4 2026
Completed enrollment of the Phase 2 trial of ZORYVE foam 0.3% in individuals with vitiligo with disclosure of topline results and decision on program advancement anticipated in Q4 of 2026Source filing
ZORYVE foam 0.3% — Topline data
Q1 2027
The Company expects to report results, as well as decisions on program advancement in these indications, in the fourth quarter of 2026 and first quarter of 2027, respectively.Source filing
ZORYVE cream 0.05% — PDUFA
Feb 23
The FDA accepted an sNDA for ZORYVE cream 0.05% to expand the indication for the treatment of mild to moderate atopic dermatitis in infants aged 3 to 24 months with a Prescription Drug User Fee Act (PDUFA) target action date of February 23, 2027.Source filing